Highlights
•
Vaccination with CPV-2b prevents clinical signs following virulent heterologous challenge.
•
Vaccination prevents virus excretion and leucopenia following challenge.
•
Vaccination induces cross neutral antibody responses to CPV-2, CPV-2a and CPV-2c.ฃ